IgA quantification as a good predictor of the neutralizing antibodies levels after vaccination against SARS-CoV-2

• Published in: Journal of clinical virology plus Vol. 2; no. 4; p. 100121
• Main Authors: Fernandes-Siqueira, Lorena O., Sousa, Bruna G., Cleto, Carlos E., Wermelinger, Luciana S., Caetano, Beatriz L.L., Pacheco, Agatha R., Costa, Simone M., Almeida, Fabio C.L., Ferreira, Gustavo C., Salmon, Didier, Alves, Ada M.B., Da Poian, Andrea T.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.11.2022; Elsevier
• Subjects: IgA; IgG; Neutralizing antibodies; SARS-CoV-2; Vaccination; IgG; SARS-CoV-2; IgA; Neutralizing antibodies; Vaccination
• ISSN: 2667-0380; 2667-0380
• DOI: 10.1016/j.jcvp.2022.100121

•Serological response to SARS-CoV-2 was compared among vaccinated individuals.•CoronaVac, ChAdOx-1 or BNT162b2 induce different serum immunoglobulin profile.•Neutralizing antibodies’ levels correspond to the IgA response after vaccination. Vaccination against COVID-19 was implemented very quickly, but the emergence of new variants that can evade the previous acquired immunological protection highlights the importance of understanding the mechanisms involved in the immune response generated after SARS-CoV-2 infection or vaccination. Since most of our knowledge on the humoral immunity generated against SARS-CoV-2 has been obtained from studies with infected patients before vaccination, our goal here was to evaluate seroconversion and its correlation with the titers of neutralizing antibodies (NAbs) in individuals who received the complete initial recommended vaccination schedule with three different vaccines. We analyzed serum IgG, IgA and total NAbs against the trimeric SARS-CoV-2 Spike (S) protein or its receptor binding domain (RBD) in blood samples collected from 118 healthy individuals without known previous infection, before and after receiving the first and the second dose of CoronaVac (n = 18), ChAdOx-1 (n = 68) or BNT162b2 (n = 32) vaccines. We found that although IgG titers were high in all sera collected after the two doses of these vaccines, NAbs amounts varies among the groups. In contrast, serum NAbs concentrations were much more comparable to the IgA levels, indicating that these antibodies would have a major neutralizing capacity against SARS-CoV-2. Altogether our data suggest that quantification of serum anti-S or anti-RBD IgA, rather than IgG, may be a valuable tool to screen NAbs and may be considered for surveillance of vaccine coverage.